Publications

Displaying 1 - 5 of 5
  • Schijven, D., Postema, M., Fukunaga, M., Matsumoto, J., Miura, K., De Zwarte, S. M., Van Haren, N. E. M., Cahn, W., Hulshoff Pol, H. E., Kahn, R. S., Ayesa-Arriola, R., Ortiz-García de la Foz, V., Tordesillas-Gutierrez, D., Vázquez-Bourgon, J., Crespo-Facorro, B., Alnæs, D., Dahl, A., Westlye, L. T., Agartz, I., Andreassen, O. A. and 129 moreSchijven, D., Postema, M., Fukunaga, M., Matsumoto, J., Miura, K., De Zwarte, S. M., Van Haren, N. E. M., Cahn, W., Hulshoff Pol, H. E., Kahn, R. S., Ayesa-Arriola, R., Ortiz-García de la Foz, V., Tordesillas-Gutierrez, D., Vázquez-Bourgon, J., Crespo-Facorro, B., Alnæs, D., Dahl, A., Westlye, L. T., Agartz, I., Andreassen, O. A., Jönsson, E. G., Kochunov, P., Bruggemann, J. M., Catts, S. V., Michie, P. T., Mowry, B. J., Quidé, Y., Rasser, P. E., Schall, U., Scott, R. J., Carr, V. J., Green, M. J., Henskens, F. A., Loughland, C. M., Pantelis, C., Weickert, C. S., Weickert, T. W., De Haan, L., Brosch, K., Pfarr, J.-K., Ringwald, K. G., Stein, F., Jansen, A., Kircher, T. T., Nenadić, I., Krämer, B., Gruber, O., Satterthwaite, T. D., Bustillo, J., Mathalon, D. H., Preda, A., Calhoun, V. D., Ford, J. M., Potkin, S. G., Chen, J., Tan, Y., Wang, Z., Xiang, H., Fan, F., Bernardoni, F., Ehrlich, S., Fuentes-Claramonte, P., Garcia-Leon, M. A., Guerrero-Pedraza, A., Salvador, R., Sarró, S., Pomarol-Clotet, E., Ciullo, V., Piras, F., Vecchio, D., Banaj, N., Spalletta, G., Michielse, S., Van Amelsvoort, T., Dickie, E. W., Voineskos, A. N., Sim, K., Ciufolini, S., Dazzan, P., Murray, R. M., Kim, W.-S., Chung, Y.-C., Andreou, C., Schmidt, A., Borgwardt, S., McIntosh, A. M., Whalley, H. C., Lawrie, S. M., Du Plessis, S., Luckhoff, H. K., Scheffler, F., Emsley, R., Grotegerd, D., Lencer, R., Dannlowski, U., Edmond, J. T., Rootes-Murdy, K., Stephen, J. M., Mayer, A. R., Antonucci, L. A., Fazio, L., Pergola, G., Bertolino, A., Díaz-Caneja, C. M., Janssen, J., Lois, N. G., Arango, C., Tomyshev, A. S., Lebedeva, I., Cervenka, S., Sellgren, C. M., Georgiadis, F., Kirschner, M., Kaiser, S., Hajek, T., Skoch, A., Spaniel, F., Kim, M., Kwak, Y. B., Oh, S., Kwon, J. S., James, A., Bakker, G., Knöchel, C., Stäblein, M., Oertel, V., Uhlmann, A., Howells, F. M., Stein, D. J., Temmingh, H. S., Diaz-Zuluaga, A. M., Pineda-Zapata, J. A., López-Jaramillo, C., Homan, S., Ji, E., Surbeck, W., Homan, P., Fisher, S. E., Franke, B., Glahn, D. C., Gur, R. C., Hashimoto, R., Jahanshad, N., Luders, E., Medland, S. E., Thompson, P. M., Turner, J. A., Van Erp, T. G., & Francks, C. (2023). Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium. Proceedings of the National Academy of Sciences of the United States of America, 120(14): e2213880120. doi:10.1073/pnas.2213880120.

    Abstract

    Left–right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case–control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case–control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case–control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case–control status. Subtle case–control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia.

    Additional information

    Supporting Information link to preprint
  • Sha, Z., Schijven, D., Fisher, S. E., & Francks, C. (2023). Genetic architecture of the white matter connectome of the human brain. Science Advances, 9(7): eadd2870. doi:10.1126/sciadv.add2870.

    Abstract

    White matter tracts form the structural basis of large-scale brain networks. We applied brain-wide tractography to diffusion images from 30,810 adults (U.K. Biobank) and found significant heritability for 90 node-level and 851 edge-level network connectivity measures. Multivariate genome-wide association analyses identified 325 genetic loci, of which 80% had not been previously associated with brain metrics. Enrichment analyses implicated neurodevelopmental processes including neurogenesis, neural differentiation, neural migration, neural projection guidance, and axon development, as well as prenatal brain expression especially in stem cells, astrocytes, microglia, and neurons. The multivariate association profiles implicated 31 loci in connectivity between core regions of the left-hemisphere language network. Polygenic scores for psychiatric, neurological, and behavioral traits also showed significant multivariate associations with structural connectivity, each implicating distinct sets of brain regions with trait-relevant functional profiles. This large-scale mapping study revealed common genetic contributions to variation in the structural connectome of the human brain.
  • Hebebrand, J., Peters, T., Schijven, D., Hebebrand, M., Grasemann, C., Winkler, T. W., Heid, I. M., Antel, J., Föcker, M., Tegeler, L., Brauner, L., Adan, R. A., Luykx, J. J., Correll, C. U., König, I. R., Hinney, A., & Libuda, L. (2018). The role of genetic variation of human metabolism for BMI, mental traits and mental disorders. Molecular Metabolism, 12, 1-11. doi:10.1016/j.molmet.2018.03.015.

    Abstract

    Objective
    The aim was to assess whether loci associated with metabolic traits also have a significant role in BMI and mental traits/disorders
    Methods
    We first assessed the number of single nucleotide polymorphisms (SNPs) with genome-wide significance for human metabolism (NHGRI-EBI Catalog). These 516 SNPs (216 independent loci) were looked-up in genome-wide association studies for association with body mass index (BMI) and the mental traits/disorders educational attainment, neuroticism, schizophrenia, well-being, anxiety, depressive symptoms, major depressive disorder, autism-spectrum disorder, attention-deficit/hyperactivity disorder, Alzheimer's disease, bipolar disorder, aggressive behavior, and internalizing problems. A strict significance threshold of p < 6.92 × 10−6 was based on the correction for 516 SNPs and all 14 phenotypes, a second less conservative threshold (p < 9.69 × 10−5) on the correction for the 516 SNPs only.
    Results
    19 SNPs located in nine independent loci revealed p-values < 6.92 × 10−6; the less strict criterion was met by 41 SNPs in 24 independent loci. BMI and schizophrenia showed the most pronounced genetic overlap with human metabolism with three loci each meeting the strict significance threshold. Overall, genetic variation associated with estimated glomerular filtration rate showed up frequently; single metabolite SNPs were associated with more than one phenotype. Replications in independent samples were obtained for BMI and educational attainment.
    Conclusions
    Approximately 5–10% of the regions involved in the regulation of blood/urine metabolite levels seem to also play a role in BMI and mental traits/disorders and related phenotypes. If validated in metabolomic studies of the respective phenotypes, the associated blood/urine metabolites may enable novel preventive and therapeutic strategies.
  • Schijven, D., Kofink, D., Tragante, V., Verkerke, M., Pulit, S. L., Kahn, R. S., Veldink, J. H., Vinkers, C. H., Boks, M. P., & Luykx, J. J. (2018). Comprehensive pathway analyses of schizophrenia risk loci point to dysfunctional postsynaptic signaling. Schizophrenia Research, 199, 195-202. doi:10.1016/j.schres.2018.03.032.

    Abstract

    Large-scale genome-wide association studies (GWAS) have implicated many low-penetrance loci in schizophrenia. However, its pathological mechanisms are poorly understood, which in turn hampers the development of novel pharmacological treatments. Pathway and gene set analyses carry the potential to generate hypotheses about disease mechanisms and have provided biological context to genome-wide data of schizophrenia. We aimed to examine which biological processes are likely candidates to underlie schizophrenia by integrating novel and powerful pathway analysis tools using data from the largest Psychiatric Genomics Consortium schizophrenia GWAS (N=79,845) and the most recent 2018 schizophrenia GWAS (N=105,318). By applying a primary unbiased analysis (Multi-marker Analysis of GenoMic Annotation; MAGMA) to weigh the role of biological processes from the Molecular Signatures Database (MSigDB), we identified enrichment of common variants in synaptic plasticity and neuron differentiation gene sets. We supported these findings using MAGMA, Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) and Interval Enrichment Analysis (INRICH) on detailed synaptic signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and found enrichment in mainly the dopaminergic and cholinergic synapses. Moreover, shared genes involved in these neurotransmitter systems had a large contribution to the observed enrichment, protein products of top genes in these pathways showed more direct and indirect interactions than expected by chance, and expression profiles of these genes were largely similar among brain tissues. In conclusion, we provide strong and consistent genetics and protein-interaction informed evidence for the role of postsynaptic signaling processes in schizophrenia, opening avenues for future translational and psychopharmacological studies.
  • Iliadis, S. I., Sylvén, S., Hellgren, C., Olivier, J. D., Schijven, D., Comasco, E., Chrousos, G. P., Sundström Poromaa, I., & Skalkidou, A. (2016). Mid-pregnancy corticotropin-releasing hormone levels in association with postpartum depressive symptoms. Depression and Anxiety, 33(11), 1023-1030. doi:10.1002/da.22529.

    Abstract

    Background Peripartum depression is a common cause of pregnancy- and postpartum-related morbidity. The production of corticotropin-releasing hormone (CRH) from the placenta alters the profile of hypothalamus–pituitary–adrenal axis hormones and may be associated with postpartum depression. The purpose of this study was to assess, in nondepressed pregnant women, the possible association between CRH levels in pregnancy and depressive symptoms postpartum. Methods A questionnaire containing demographic data and the Edinburgh Postnatal Depression Scale (EPDS) was filled in gestational weeks 17 and 32, and 6 week postpartum. Blood samples were collected in week 17 for assessment of CRH. A logistic regression model was constructed, using postpartum EPDS score as the dependent variable and log-transformed CRH levels as the independent variable. Confounding factors were included in the model. Subanalyses after exclusion of study subjects with preterm birth, newborns small for gestational age (SGA), and women on corticosteroids were performed. Results Five hundred thirty-five women without depressive symptoms during pregnancy were included. Logistic regression showed an association between high CRH levels in gestational week 17 and postpartum depressive symptoms, before and after controlling for several confounders (unadjusted OR = 1.11, 95% CI 1.01–1.22; adjusted OR = 1.13, 95% CI 1.02–1.26; per 0.1 unit increase in log CRH). Exclusion of women with preterm birth and newborns SGA as well as women who used inhalation corticosteroids during pregnancy did not alter the results. Conclusions This study suggests an association between high CRH levels in gestational week 17 and the development of postpartum depressive symptoms, among women without depressive symptoms during pregnancy.

Share this page